SEC Form 4 · accession 0001493152-16-010067
Ernexa Therapeutics Inc. · ERNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dave Brian Miller
Officer — SVP Marketing
Period of report
May 16, 2016
Accepted (ET)
May 18, 2016 · 5:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000748592
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 17, 2016 | P | 20,000 | $0.1669 | A | 60,000 | D | |
| Common Stock | May 17, 2016 | P | 10,000 | $0.17 | A | 70,000 | D | |
| Common Stock | May 17, 2016 | P | 10,000 | $0.165 | A | 80,000 | D | |
| Common Stock | May 17, 2016 | P | 10,000 | $0.1745 | A | 90,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.18 | May 16, 2016 | A | 500,000 | A | May 16, 2017 | May 15, 2026 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1Stock option granted under the NTN Buzztime, Inc. Amended 2010 Performance Incentive Plan. The stock option shall vest and become exercisable at the rate of 25% of the shares underlying the option on May 16, 2017 and the remaining 75% of the total number of shares of common stock shall become vested and exercisable in a series of 36 substantially equal monthly installments thereafter.